Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries presented data analyses for two of its speciality medicines – ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U – from its dermatology portfolio, providing insights to healthcare providers treating patients who have or are at risk for different types of skin cancer. These data analyses were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.
In the ‘Arena of Valour,’ a popular online game, the character Ilumia is a wizard endowed with powers to inflict damage and protect others. Victory is assured with Ilumia by your side, claim gaming platforms.
Sun PharmaBSE -0.36 %, Dr. Reddy’s, GlenmarkBSE -0.33 %, Zydus Cadila, AurobindoBSE 1.03 % and their ilk are embracing a new life. Deploying investments to bolster indigenous research and lapping up late clinical stage drugs or new brands is heralding a seismic shift from churning copies of drugs to the daunting world of innovative or differentiated brands.
Drug major Sun Pharmaceutical IndustriesBSE -0.76 % today said it it will acquire a branded oncology product, Odomzo, from NovartisBSE -0.31 % for an upfront payment of $ 175 million.